CD8A and neoplasm: The density of tumor-infiltrating CD8+ T cells in IMbrave150 baseline tumor samples was analyzed and patients with a high density of tumor-infiltrating CD8+ T cells (defined by the split median) had significantly longer OS when treated with atezolizumab + bevacizumab combination therapy compared with those treated with sorafenib [73].